2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCareInnovative Chemotherapy‐free Approaches for the Treatment of Peripheral T‐Cell Lymphoma
Marchi E, Sawas A, Ma H, Scotto L, Montanari F. Innovative Chemotherapy‐free Approaches for the Treatment of Peripheral T‐Cell Lymphoma. 2021, 367-377. DOI: 10.1002/9781119671336.ch27.Peer-Reviewed Original ResearchPrimary cutaneous T-cell lymphomaT-cell lymphomaHypomethylating agentPeripheral T-cell lymphomaCutaneous T-cell lymphomaChemotherapy-free approachConventional cytotoxic chemotherapyCare of patientsDrug-drug combinationsNew therapeutic agentsCytotoxic chemotherapyPreclinical observationsTherapeutic agentsKinase inhibitorsPhase ICancer medicineProteasome inhibitorsLines of evidenceLymphomaSubsequent developmentInhibitorsDrugsAgentsChemotherapyPatients
2020
The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Marchi E, Ma H, Montanari F, Sawas A, Lue J, Deng C, Whitfield K, Klein S, Scotto L, Jain S, Lister J, Benanni N, Francescone M, Kim W, Zinzani P, O'Connor O. The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Journal Of Clinical Oncology 2020, 38: 8049-8049. DOI: 10.1200/jco.2020.38.15_suppl.8049.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaGrade 3 hyponatremiaPhase 1b studyTreatment-related deathsGrade 3 thrombocytopeniaImmune checkpoint inhibitorsPreliminary clinical dataDose of drugPre-clinical modelsCancer-testis antigensCases of toxicityExperienced progressionFebrile neutropeniaRefractory PTCLStable diseaseComplete remissionPartial remissionPatient characteristicsClinical dataPharmacodynamic studiesTestis antigensPatientsTriple combinationResponse rate